| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |